An ingenious technique based on the usage of fluorone‐based dye; pyrosin B in prucalopride assay in different matrices through an “on–off” dye native fluorescence probe

Prucalopride (PCD), is a modern medication approved by the United States in 2018 to alleviate constipation caused by motility issues. PCD demonstrates a strong affinity and selectivity toward the 5‐HT4 receptor. The study here introduces a feasible, direct, non‐extractive, and affordable pathway for PCD analytical tracking. The fluorimetric study is based on the on–off effect on the emission amplitude of fluorone‐based dye (pyrosin B). In a one‐pot experiment, the complex between PCD and pyrosin B is formed instantly in an acidic medium. Correlation between decreased pyrosin B emission and PCD concentrations provides a linear calibration plot from 50 to 900 ng/mL. PCD–dye complex system affecting variables were meticulously tuned. The values of the estimated limit of quantitation and limit of detection for the current methodology were 47.5 and 15.7 ng/mL, respectively. Conformity of the strategy validity was achieved by a comprehensive study of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use criteria. The method was convincingly applied for PCD assay in tablets and content uniformity investigation. Furthermore, PCD tracking in the spiked biological fluid was applied. Finally, the method uses distilled water as dispersing medium which rise accommodation with the green chemistry principle. Simple, accurate, and non‐extractive spectrofluorimetric method for the determination of prucalopride (PCD). The strategy utilizes fluorescence quenching phenomena resulting from the dual complex association between pyrosin B and PCD. The method was applied successfully for the dosage form and human plasma analysis. The method was validated and applied according to the instructions of ICH and FDA guidelines.